All In Biotech

Drug Trial Radar · NCT06712810

Q702 for the Treatment of Patients With Hematologic Malignancies

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Aug 27, 2025

Primary completion

Sep 15, 2030

Study completion Sep 15, 2030

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Histiocytic Sarcoma
  • Malignant Histiocytosis
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Chronic Myelomonocytic Leukemia
  • Recurrent Follicular Lymphoma
  • Recurrent Langerhans Cell Histiocytosis
  • Recurrent Lymphoplasmacytic Lymphoma
  • Recurrent Myelodysplastic Syndrome
  • Recurrent Myelofibrosis
  • Recurrent Small Lymphocytic Lymphoma
  • Recurrent Waldenstrom Macroglobulinemia
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Erdheim-Chester Disease
  • Refractory Follicular Lymphoma
  • Refractory Langerhans Cell Histiocytosis
  • Refractory Lymphoplasmacytic Lymphoma
  • Refractory Myelodysplastic Syndrome
  • Refractory Myelofibrosis
  • Refractory Small Lymphocytic Lymphoma
  • Refractory Waldenstrom Macroglobulinemia
  • Rosai-Dorfman-Destombes Disease
  • Primary Central Nervous System Lymphoma
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Recurrent Erdheim-Chester Disease
  • Recurrent Fibroblastic Reticular Cell Sarcoma
  • Recurrent Histiocytic Sarcoma
  • Recurrent Interdigitating Dendritic Cell Sarcoma
  • Recurrent Rosai-Dorfman-Destombes Disease
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Refractory Fibroblastic Reticular Cell Sarcoma
  • Refractory Histiocytic Sarcoma
  • Refractory Interdigitating Dendritic Cell Sarcoma
  • Refractory Rosai-Dorfman-Destombes Disease

Interventions

  • Axl/Mer/CSF1R Inhibitor Q702Drug

    Given PO

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspiration

  • Computed TomographyProcedure

    Undergo CT scan

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Positron Emission TomographyProcedure

    Undergo PET scan

  • Survey AdministrationOther

    Ancillary study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicityTime frame: Up to 3 years
  2. Overall response rateTime frame: Up to 3 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.